Ad-hoc | 31 August 2009 14:23
aap Implantate AG / Agreement
31.08.2009
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
EMCM B.V., a Dutch subsidiary and member of the aap Implantate AG Group, a
medical technology company listed in the Frankfurt Stock Exchange's Prime
Standard segment, today signed with a distribution partner an open-ended
exclusive license agreement on the utilization of the intellectual property
of a product in the field of medical aesthetics with a total value of EUR
3.0 million. By the terms of the agreement, aap will continue to
manufacture and supply the product under contract.
This contract relate to a line of business that is no longer core business
area for aap and clearly testify to the implementation of the Group's
strategic realignment and its focus on Ortho/Trauma/Spine business.
Due to the effects of the above-mentioned contract at the sales and
earnings level, the aap Management Board sees its forecast of profitable
growth this financial year confirmed. It specifically anticipates an EBITDA
of between EUR 5.0 million and EUR 7.0 million.
Together with another recent contract with a global partner to supply bone
cement for use in spinal surgery and traumatology, also the groundwork for
business development in 2010 is laid. Shipping of the bone cement will
begin in the current financial year, and the signing of this agreement
confirms once again aap's leading position in this field.
Contact:
Bei Rückfragen wenden Sie sich bitte an:
aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications &
Legal Affairs; Lorenzweg 5; D-12099 Berlin
Tel.: ++49/30/750 19 - 133; Fax.: ++49/30/750 19 - 290; n.huedepohl@aap.de
31.08.2009 Financial News transmitted by DGAP
---------------------------------------------------------------------------
Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Deutschland
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: aap@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hannover, München, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------